Anhui Chest Hospital

The trials here

What the 24 trials at this site are about, from their registry records.

Conditions

• Lung cancer8 trials
• COPD6 trials
• Tuberculosis4 trials
• Asthma2 trials
• Bronchiectasis2 trials
• Idiopathic pulmonary fibrosis2 trials

Phase

• Phase 39 trials
• Phase 24 trials
• Phase 42 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Recruiting9 trials
• Active, not recruiting6 trials
• Completed6 trials
• Not yet recruiting3 trials

Lead sponsor

• Shanghai Pulmonary Hospital, Shanghai, China3 trials
• Amgen2 trials
• First Affiliated Hospital of Ningbo University2 trials
• Hoffmann-La Roche2 trials
• InSilico Medicine Hong Kong Limited2 trials
• and 13 more

Running trials

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source

  Contact: Qinhan Chen

• Not yet recruiting

  Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

  NCT07393438· Phase 2· Shanghai Pulmonary Hospital, Shanghai, China· Source

  Contact: Wang Hua, MD

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· BioNTech SE· Source

• Recruiting

  Clinical Study of the Pulsed Electric Field Ablation System in Chronic Obstructive Pulmonary Disease

  NCT07068438· Suzhou Hengruihongyuan Medical Technology Co. LTD· Source

  Contact: Ling Xu

• Recruiting

  Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

  NCT07213765· Phase 4· Bin Cao· Source

  Contact: Siwei Gu, M.D.

• Recruiting

  A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

  NCT07292714· Phase 2· Mabwell (Shanghai) Bioscience Co., Ltd.· Source

  Contact: Yongchang Sun, Doctor

• Recruiting

  Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy

  NCT07030881· First Affiliated Hospital of Ningbo University· Source

  Contact: Wenjuan Xia

• Recruiting

  Remote Anxiety Management for ICS-resistant Asthma Study

  NCT06732141· First Affiliated Hospital of Ningbo University· Source

  Contact: Wenjuan Xia

• Active, not recruiting

  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

  NCT06649721· Phase 3· Huashan Hospital· Source

• Recruiting

  Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)

  NCT06760273· Shanghai Pulmonary Hospital, Shanghai, China· Source

  Contact: Hua Niu, MD

• Active, not recruiting

  A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

  NCT06225804· Phase 1· Abbisko Therapeutics Co, Ltd· Source

• Active, not recruiting

  Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

  NCT06081361· Phase 3· Beijing Chest Hospital· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

  NCT05353257· Phase 3· Shanghai Henlius Biotech· Source

• Recruiting

  Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm

  NCT04937283· Shanghai Pulmonary Hospital, Shanghai, China· Source

  Contact: Ning Xu

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD4 recruiting
• Lung cancer3 recruiting
• Asthma2 recruiting
• Bronchiectasis1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Tuberculosis1 recruiting

Closed trials

• Completed

  HTA of NIVATS Based on RWE

  NCT06574295· Fudan University· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above

  NCT05899179· Phase 3· Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Completed

  A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05595642· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

  NCT03940703· Phase 2· EMD Serono Research & Development Institute, Inc.· Source